Beasley Allen and Talcum Powder Litigation: 2026 Status and Verdicts

Beasley Allen was for years one of the plaintiffs’ firms at the center of the talcum powder litigation against Johnson & Johnson, holding court-appointed leadership in the federal multidistrict litigation and serving as co-counsel on the 2018 St. Louis judgment of roughly $4.69 billion, later reduced on appeal to about $2.12 billion — but during 2026 the firm was disqualified from leadership and from thousands of individual talc cases by courts in New Jersey, Pennsylvania and the federal MDL over its dealings with a former Johnson & Johnson lawyer. The firm disputes those rulings and has said it expects to prevail on appeal.

That reversal happened alongside the biggest substantive development in the case’s history. In July 2026 Johnson & Johnson proposed a roughly $5.5 billion settlement of approximately 76,000 ovarian cancer claims, negotiated in the tort system rather than through bankruptcy, and conditioned on law firms representing at least 95 percent of eligible claims signing on. This article sets out the firm’s role and its current status, the underlying science stated fairly, the verdicts and what happened to them on appeal, the three failed bankruptcy attempts, where the litigation actually stands as of September 2026, and what someone considering a claim should realistically expect. It is general information about ongoing litigation and is not legal advice; anyone with a potential claim should consult a licensed attorney about their own circumstances, because deadlines and requirements vary substantially by state and this docket is moving quickly.

Who Beasley Allen Is

Beasley Allen was founded in 1979 by Jere Beasley, who had previously served as Lieutenant Governor of Alabama. The firm represents plaintiffs exclusively — it does not defend corporations — and is organized into sections covering mass torts, personal injury, consumer fraud, toxic torts, and employment law.

Its national profile came from earlier mass tort work, including pharmaceutical litigation and its role for the State of Alabama in litigation arising from the 2010 Deepwater Horizon oil spill. Within the talc litigation, attorneys from the firm’s mass torts section — led by Andy Birchfield, with Leigh O’Dell serving in a court-appointed co-lead role on the plaintiffs’ steering committee — handled discovery coordination, expert development, and trial work across multiple jurisdictions for the better part of a decade. Court-appointed leadership positions in an MDL are significant: they carry responsibility for common discovery, expert witness strategy, and settlement negotiation on behalf of thousands of claimants, not just a firm’s own clients. The firm’s Beasley Allen Law Firm office in Atlanta handles a share of that regional caseload.

Timeline: Beasley Allen and the Talc Litigation at a Glance

The talc story spans more than a decade, and the order of events explains a lot about where things stand. The milestones below are drawn from the court rulings and filings discussed in this article.

The 2026 Disqualifications and Why They Matter

This is the development that most existing coverage of Beasley Allen and talc has not caught up with, and it changes the practical answer to “should I call this firm about a talc claim.”

The dispute centers on James Conlan, a lawyer who previously represented Johnson & Johnson at Faegre Drinker Biddle & Reath and who later founded Legacy Liability Solutions. Beasley Allen worked with Conlan on a proposed structure under which Johnson & Johnson’s talc liabilities would be bundled into an offshoot entity and sold to him — an alternative to the company’s own bankruptcy strategy. Johnson & Johnson moved to disqualify the firm, arguing that Conlan’s prior defense work gave him access to confidential information about the company’s talc position that could not be walled off.

The language in the rulings was unusually pointed. Judge Singh wrote that “personal antagonism and poor choices render Beasley Allen’s continued leadership problematic,” and that “all plaintiffs involved in this matter deserve to be represented by counsel who take seriously their ethical obligations and who are above reproach.” Judge Roberts in Philadelphia wrote that “doubt created by infidelity can never be cured.”

Beasley Allen’s position, stated in court filings, is that it never employed or controlled Conlan, that the disqualification standard was misapplied, and that a ruling of this kind discourages creative approaches to resolving mass claims. The firm has said it is likely to prevail on appeal to the Third Circuit. Other plaintiffs’ firms began applying to fill the vacated leadership roles during 2026.

What this means for a claimant. Disqualification of a firm from leadership or from a group of cases does not extinguish anyone’s claim, and it is not a finding that the underlying cases lack merit. It does mean that if you were represented by the firm in an affected jurisdiction, your case was reassigned, and that the firm no longer speaks for the plaintiff group in the federal MDL. If you are choosing counsel now, this is a reasonable thing to ask any firm about directly — including asking who would actually try your case. Our guide to recognizing when a lawyer is not acting in your interest covers the warning signs worth watching for in any representation.

The Underlying Science, Stated Fairly

Talc is a naturally occurring magnesium silicate mineral, valued in cosmetics for absorbing moisture and reducing friction. The health concern rests on two related but distinct theories, and it is worth separating them because they carry different evidentiary weight.

Theory one: asbestos contamination. Talc and asbestos can form in geologically adjacent deposits, which creates a risk of cross-contamination during mining unless the ore is carefully sourced and tested. Asbestos is a recognized human carcinogen and the established cause of mesothelioma. This is the stronger causal chain, and it underpins the mesothelioma claims. Anyone facing that diagnosis may find our overview of what victims should know about a mesothelioma diagnosis a useful starting point on the medical and legal picture.

Theory two: talc itself and ovarian cancer. Plaintiffs allege that talc particles applied to the perineal area can migrate to the ovaries and cause chronic inflammation over years of use, elevating ovarian cancer risk. The epidemiological record here is genuinely contested. Case-control studies dating back to Cramer’s work in 1982 have repeatedly found modest positive associations; several large prospective cohort studies have not found a statistically significant association. Both sides have credentialed experts, and this disagreement is the core scientific battleground of the litigation.

Regulatory classifications

• Asbestos-containing talc has long been classified by the International Agency for Research on Cancer as carcinogenic to humans (Group 1).
• Perineal use of talc-based body powder was classified by IARC in 2006 as possibly carcinogenic to humans (Group 2B).
• In 2024, an IARC working group reclassified talc itself as probably carcinogenic to humans (Group 2A), citing limited evidence in humans for ovarian cancer, sufficient evidence in experimental animals, and strong mechanistic evidence. That evaluation was published as IARC Monographs Volume 136. IARC classifications describe the strength of evidence that something can cause cancer, not the magnitude of risk in ordinary use — a distinction that both plaintiffs and defendants have characterized to their advantage.

Alongside the scientific record, plaintiffs have relied heavily on documentary evidence. A widely reported 2018 Reuters investigation described internal Johnson & Johnson documents indicating that the company was aware, over a period spanning decades, of test results showing small amounts of asbestos in its talc, and that this information was not disclosed to regulators or the public. In May 2026, former FDA Commissioner David Kessler testified as a plaintiffs’ witness in a Los Angeles trial that the company had misled the agency for decades about asbestos concerns. Johnson & Johnson disputes that characterization and maintains, on its public talc information site, that decades of independent testing confirm its talc has always been asbestos-free and does not cause cancer.

Major Verdicts and What Happened to Them

Jury verdicts in this litigation have produced headline numbers, but very few have been paid at the figure announced. Appellate reduction, reversal, and retrial are the norm in mass tort litigation, and any honest account has to include what happened afterward.

The Ingham case remains the largest gross award. Twenty-two women and their families brought consolidated claims in Missouri state court, and Beasley Allen served as co-counsel. The jury’s punitive award was substantially reduced by the Missouri Court of Appeals, but the reduced judgment survived review and was ultimately paid with interest, making it one of the largest product liability recoveries in American history.

The December 2025 Craft verdict is the more current data point and, by most accounts, the largest talc award ever returned for a single plaintiff. It is also a useful illustration of how punitive damages dominate these numbers: the compensatory component was $60 million, and the remaining $1.5 billion was punitive. Punitive awards of that ratio routinely face constitutional challenge on appeal, and Johnson & Johnson has said it will bring one.

It is equally important to note that Johnson & Johnson has prevailed in a meaningful number of trials, and several plaintiff verdicts have been overturned. Anyone assessing the strength of a potential claim should not treat the largest reported verdicts as representative of typical outcomes.

Johnson & Johnson’s Response and the Bankruptcy Strategy

The company’s public position has been consistent: it denies that its talc products contain asbestos, denies that they cause ovarian cancer or mesothelioma, and characterizes the plaintiffs’ science as methodologically flawed. In May 2020 it discontinued talc-based baby powder in the United States and Canada, reformulating with cornstarch, and in 2022 announced it would end talc-based sales globally. The company attributed those decisions to declining demand and misinformation rather than to safety concerns.

The more consequential development was procedural. Beginning in October 2021, Johnson & Johnson pursued a corporate restructuring — widely described as a “Texas two-step” — in which talc liabilities were assigned to a newly created subsidiary that then filed for Chapter 11 bankruptcy, with the aim of resolving all present and future claims through a bankruptcy trust rather than through jury trials.

• First attempt (2021): LTL Management LLC filed Chapter 11. In January 2023 the Third Circuit Court of Appeals dismissed the case, holding that the entity was not in financial distress and therefore could not properly access bankruptcy protection.
• Second attempt (2023): A refiling accompanied by a settlement proposal of roughly $8.9 billion was also dismissed later that year.
• Third attempt (2024): A prepackaged filing through a further subsidiary sought approval of a plan with a present value of about $6.48 billion, payable over 25 years and therefore often quoted at an $8 billion to $9 billion nominal figure. Claimants were given three months to vote. Andy Birchfield of Beasley Allen said at the time that “any bankruptcy based on this solicitation and vote will be found fraudulent.” A Texas bankruptcy court rejected the plan on March 31, 2025, finding that the company did not belong in bankruptcy, and Johnson & Johnson said it would return to defending cases in the tort system.

Beasley Allen was among the firms that publicly and formally opposed each of these filings, arguing that a solvent multinational should not be able to use the bankruptcy code to cap and compress claims that would otherwise be tried before juries. Supporters of the strategy argued the opposite — that an aggregate trust delivers compensation faster and more equitably than a decades-long trial calendar in which early claimants recover heavily and later ones may recover nothing. The firm’s own alternative, the Conlan liability-transfer structure, is what ultimately triggered its disqualification.

Where the Litigation Stands in September 2026

The federal cases are consolidated as MDL No. 2738 in the District of New Jersey before Judge Michael A. Shipp, with Magistrate Judge Rukhsanah L. Singh handling case management. It is the largest active multidistrict litigation in the federal court system: roughly 68,400 pending actions as of July 1, 2026, representing about a third of all pending federal MDL actions nationwide, rising to roughly 69,000 by September. Current counts are published by the Judicial Panel on Multidistrict Litigation. Several thousand further cases are pending in state courts, principally New Jersey, Pennsylvania, Missouri and California.

The last twelve months moved faster than the previous five years:

• January 20, 2026 — expert ruling. Retired U.S. District Judge Freda Wolfson, appointed as special master, issued a report and recommendation to Judge Shipp on the Rule 702 challenges. She found that the plaintiffs’ general causation experts had applied reliable methodologies to the epidemiological evidence on genital talc use and ovarian cancer, allowing epidemiology, gynecologic oncology and toxicology testimony to proceed. She recommended excluding several peripheral theories, including opinions tying heavy metals and fragrance chemicals in the products to cancer, and the inhalation and lymphatic migration and macrophage-impairment mechanisms. Defense experts were likewise permitted to testify that talc cannot cause ovarian cancer, setting up a straight credibility contest at trial.
• May 2026 — expert withdrawals. Plaintiffs withdrew two central specific-causation experts, Dr. Judith Wolf and Dr. Daniel L. Clarke-Pearson, whose opinions had been reserved for evidentiary hearings. General causation asks whether talc can cause the disease; specific causation asks whether it caused this plaintiff’s disease. Withdrawing the specific-causation experts left a structural gap.
• July 22, 2026 — order to show cause. Judge Singh directed plaintiffs to explain why their remaining claims should not be dismissed for inability to prove specific causation. This was, in practical terms, the moment the leverage in the case shifted.
• Late July 2026 — the settlement proposal. Johnson & Johnson disclosed in an 8-K filing a proposal to resolve the ovarian claims for approximately $5.5 billion.
• August 3 and November 5, 2026 — case management. A hearing on how the bellwether cases would proceed was set for early August, with a final pretrial conference reported for early November.

The $5.5 billion proposal, in outline

Two cautions belong with those figures. First, as of this writing the participation threshold had not been publicly confirmed as met, and a deal conditioned on 95 percent sign-off can fail on a comparatively small holdout group. Second, a headline settlement fund divided across tens of thousands of claimants produces individual figures far below the verdict numbers that generate news coverage — the arithmetic on the 2024 bankruptcy plan implied averages in the low six figures before fees and costs, and tiering means many claimants receive substantially less than the average. The pattern is familiar from other mass torts; our breakdown of the Philips CPAP lawsuit payout per person shows how aggregate settlement funds translate into individual awards in practice.

Because this is a fast-moving area, anyone relying on this page should verify the current status. Court dockets, the JPML statistics, and a consultation with a licensed attorney are the appropriate sources for a decision, not any single article.

What a Potential Claimant Should Know

If you or a family member used talc-based powder and were later diagnosed with ovarian cancer or mesothelioma, the following practical points apply in most jurisdictions. None of them substitute for advice from a lawyer licensed in your state.

• Deadlines are strict and vary widely. Statutes of limitation for personal injury and wrongful death commonly range from one to six years, and the clock may start at diagnosis, at the date you reasonably should have connected the illness to the product, or at death. Missing the deadline generally ends a claim regardless of its merits.
• Timing relative to the settlement matters now. The 2026 proposal covers pending claims. Someone diagnosed after it closes would, on the reported terms, need to bring an individual lawsuit rather than participate — which makes prompt advice more valuable than it was a year ago.
• Ovarian and mesothelioma claims are on different tracks. The proposed settlement addresses ovarian cancer claims. Mesothelioma claims are being handled separately and continue to be tried, as the December 2025 Baltimore verdict shows.
• Documentation matters more than recollection. Medical records establishing the diagnosis and its type, pathology reports, purchase history where available, and testimony from family members about product use over time all carry weight.
• Diagnosis specificity is critical. Epithelial ovarian cancer and mesothelioma are the diagnoses at the center of this litigation. Other cancers are generally not part of it.
• Specific causation is now the pressure point. After the expert withdrawals and the show-cause order, the question of whether a particular plaintiff’s disease can be attributed to talc has become the decisive one in the federal docket. Expect any competent firm to interrogate your medical history and use pattern closely before taking the case.
• Duration and pattern of use are relevant. Claims typically involve years of regular use, and details of how and where the product was applied are part of the record.
• Fees are contingent. Plaintiffs’ firms in mass torts almost always work on contingency, commonly one-third to 40 percent of any recovery, with case costs handled separately. Ask any firm to explain in writing how costs are treated if the case is lost.
• Consultations are typically free, and speaking with more than one firm before signing a representation agreement is entirely reasonable.
• Timelines are long. Mass tort claims routinely take several years, and the bankruptcy stays in this particular litigation added further delay.

Choosing counsel with genuine trial experience in this specific area matters. Many firms advertise heavily in mass torts and then refer cases onward to litigating firms; there is nothing improper about that, but you are entitled to ask who will actually handle the case, whether that firm is currently disqualified in your jurisdiction, and how it will advise you on whether to opt into a settlement. Our guide to finding trusted mesothelioma legal representation covers the questions worth asking.

How an Aggregate Talc Settlement Works for an Individual Claimant

For most people with a pending ovarian claim, the practical question is no longer whether there will be a trial but whether to participate in a settlement and what their share might be. Aggregate settlements in mass torts generally follow a similar pattern, although the final terms of this one will be set in the settlement documents and may differ.

1. Eligibility review. Your lawyer confirms that your diagnosis, product use and filing status fit the settlement definition. Claims outside the definition, such as mesothelioma or post-closing diagnoses on the reported terms, stay on a separate track.
2. Documentation. Medical and pathology records, proof or testimony about product use, and identity and estate documents (for wrongful death claims) are gathered and submitted to a claims administrator.
3. Points or tier assignment. Claims are typically scored or tiered using factors such as diagnosis type, age at diagnosis, severity and duration of use. That score, not the headline fund size, drives the individual amount.
4. Opt-in decision. You decide, with your lawyer, whether to accept. Declining usually means continuing to litigate individually, with the risks and delays that brings.
5. Liens and deductions. Before payment, fees, case costs and any medical liens (for example from Medicare, Medicaid or private health plans) are resolved and deducted.
6. Payment. Funds are released according to the schedule in the agreement, which on reported terms is spread across 2027 and 2028.

Questions to Ask Your Lawyer Before Opting In

• How will my claim likely be tiered, and what range of outcomes does that suggest after fees and costs?
• What happens to my case if the 95 percent participation threshold is not met?
• Which medical liens apply to me, and how will they be negotiated?
• If I decline, what are the realistic prospects and timeline for an individual trial in my jurisdiction?
• Is your firm, or any firm you refer to, affected by the 2026 disqualification rulings?
• Do you represent other claimants in the same settlement, and how are any conflicts handled?

Good counsel should answer these in writing and in plain language. If a firm pressures you to sign quickly without explaining your likely tier or the deductions, treat that as a reason to get a second opinion before committing.

How Mesothelioma Talc Claims Differ From Ovarian Claims

Although both kinds of claims involve the same products, mesothelioma cases run on a different legal and scientific footing, and anyone comparing them should understand why.

• The causal theory is narrower and better established. Mesothelioma claims turn on alleged asbestos contamination, and asbestos is a recognized cause of the disease. The fight is usually over whether the specific product contained asbestos and whether the plaintiff had other exposures, not whether asbestos can cause mesothelioma at all.
• Latency is long. Mesothelioma typically appears decades after exposure, so cases often depend on reconstructing product use from many years earlier through family testimony, purchase habits and employment history.
• Other exposure sources are scrutinized. Defendants routinely investigate occupational asbestos exposure, such as construction, shipyard or automotive work, and exposure through a family member’s work clothes.
• Multiple defendants are common. Talc suppliers, mining companies and other manufacturers may be named alongside Johnson & Johnson, and some of those entities have their own bankruptcy trusts with separate claims processes.
• Cases are moving to trial individually. Because the reported settlement covers ovarian claims, mesothelioma cases continue to be tried, which is why verdicts like the December 2025 Baltimore award keep appearing.

Common Misconceptions About the Talc Litigation

• “The big verdicts show what every case is worth.” They do not. Most headline awards were driven by punitive damages and many were reduced or reversed on appeal. Settlement shares are calculated very differently.
• “A disqualified firm means my claim is gone.” Disqualification affects who represents you, not whether your claim exists. Affected clients have had their cases reassigned.
• “The IARC classification proves talc caused my cancer.” IARC rates the strength of evidence that a substance can cause cancer. Individual cases still require proof that talc caused that person’s disease.
• “Cornstarch powder is part of the litigation.” The claims concern talc-based products. Cornstarch-based powders, which Johnson & Johnson switched to, are not the subject of these cases.
• “I can wait until the settlement is final to decide.” Statutes of limitation keep running. If you have not filed a claim, waiting can cost you the right to bring one.

How to Check the Current Status Yourself

Because this litigation changes month to month, it is worth knowing where reliable updates come from rather than relying on advertising or secondhand summaries.

1. JPML statistics: the Judicial Panel on Multidistrict Litigation publishes monthly pending-case counts for MDL No. 2738.
2. The federal docket: orders in the MDL are filed in the District of New Jersey and can be accessed through the federal courts’ PACER system.
3. Company filings: Johnson & Johnson reports material litigation developments, including settlement proposals, in its SEC filings such as 8-K and quarterly reports.
4. State court sites: New Jersey, Pennsylvania, Missouri and California courts post information about their coordinated talc proceedings.
5. Your own attorney: for anything affecting your claim, including deadlines and settlement eligibility, a licensed lawyer reviewing your file is the only reliable source.

Records Worth Gathering Now

Whether or not you have hired a lawyer, collecting the following early can save months later: the pathology report confirming your diagnosis and its type, treatment and hospital records, a written timeline of when and how you used talc products, names of family members or friends who saw that use, any receipts, photos or packaging, and, for a family member who has died, the death certificate and estate documents. Keep originals safe and give copies to counsel.

Why This Case Matters Beyond Talc

The talc litigation has become a test case for several structural questions in American civil justice.

Can a solvent corporation use a subsidiary bankruptcy to resolve mass tort liability outside the jury system? Courts have now answered in the negative three times. The 2026 settlement is the direct consequence: having failed to compel an aggregate resolution through Chapter 11, the company negotiated one in the tort system instead. That outcome will shape how other defendants approach the Texas two-step.

How should courts handle contested science? The January 2026 Rule 702 recommendation is a significant data point, because it let the core epidemiological dispute go to juries while stripping out the more speculative mechanisms. That is a middle path between wholesale exclusion and wholesale admission, and other toxic tort courts will read it.

How much leverage does control of plaintiff leadership carry? The disqualification of a long-standing co-lead firm mid-litigation, on a conflicts theory arising from settlement strategy rather than from client representation, is unusual. Whichever way the Third Circuit rules, the episode will affect how plaintiffs’ firms structure settlement negotiations and who they take advice from.

What is a mass tort claim actually worth? The gap between a $1.56 billion single-plaintiff verdict and a per-claim share of a $5.5 billion aggregate fund is the central honest tension in this area, and it is the thing potential claimants most often misunderstand.

Should You Contact Beasley Allen About a Talc Claim Today?

It depends on where you live and what kind of claim you have. The 2026 rulings removed the firm from federal MDL leadership and from specific groups of state cases in New Jersey and Philadelphia, but they did not bar it from practicing law generally, and the firm continues to handle other mass tort and personal injury matters. Its appeals may also change the picture.

A sensible approach is to treat Beasley Allen like any other firm you are evaluating. Ask directly whether it can represent you in your jurisdiction given the 2026 orders, who would handle your case day to day, how it would advise you on the ovarian settlement or on an individual mesothelioma case, and what happens to your representation if a court extends or reverses the disqualification. Compare those answers with at least one or two other firms experienced in talc or asbestos litigation. A free consultation costs nothing, and comparing several gives you a much clearer sense of your options.

The Bottom Line

Beasley Allen spent roughly a decade as one of the leading plaintiffs’ firms in the talcum powder litigation, holding court-appointed federal leadership, trying cases in multiple state courts, serving as co-counsel on the largest verdict in the litigation’s history, and opposing each of Johnson & Johnson’s three attempted bankruptcy resolutions. During 2026 courts in New Jersey, Pennsylvania and the federal MDL disqualified the firm over its work with a former Johnson & Johnson lawyer on an alternative settlement structure; the firm disputes those rulings and is appealing. Meanwhile the litigation itself reached its most consequential moment yet, with a proposed $5.5 billion tort-system settlement of around 76,000 ovarian claims hanging on a 95 percent participation threshold, mesothelioma claims continuing separately, and the underlying science on ovarian cancer still genuinely contested. If you believe you may have a claim, the single most useful step is to speak with a licensed attorney promptly — because in this area, the deadline is often the thing that decides the case.

This article is general information about ongoing public litigation and does not constitute legal advice, nor does it create an attorney-client relationship. Laws, deadlines and case statuses differ by state and change over time. Details of the 2026 settlement proposal and the pending appeals were accurate to the best available reporting at the time of writing and may since have changed. Consult a licensed attorney about your own situation.

Frequently Asked Questions

What role does Beasley Allen play in the talcum powder litigation now?

For most of the litigation’s history the firm held court-appointed leadership in the federal multidistrict litigation, MDL No. 2738 in the District of New Jersey, and served as trial counsel or co-counsel in state court cases including the 2018 Missouri case in which a jury awarded approximately $4.69 billion to 22 women, later reduced on appeal to about $2.12 billion. During 2026 that changed: courts disqualified the firm from MDL leadership on March 26, from roughly 3,600 New Jersey state cases, and from 176 Philadelphia cases. The firm disputes the rulings and has said it expects to prevail on appeal to the Third Circuit.

Why was Beasley Allen disqualified from the talc cases?

The disqualifications arose from the firm’s work with James Conlan, a lawyer who had previously defended Johnson & Johnson at Faegre Drinker Biddle & Reath and who later founded Legacy Liability Solutions. Beasley Allen collaborated with him on a plan to bundle the company’s talc liabilities into an offshoot entity for sale, as an alternative to Johnson & Johnson’s bankruptcy strategy. Courts found this gave the plaintiffs’ side improper access to confidential defense information. Magistrate Judge Rukhsanah Singh wrote that “personal antagonism and poor choices render Beasley Allen’s continued leadership problematic.” The firm says it never employed or controlled Conlan.

Is talcum powder proven to cause cancer?

The answer differs by cancer type. Asbestos is an established human carcinogen and the recognized cause of mesothelioma, so claims alleging asbestos-contaminated talc rest on a well-accepted causal mechanism. The link between talc itself and ovarian cancer is genuinely contested: case-control studies have repeatedly found modest associations, while several large prospective cohort studies have not found statistically significant ones. In 2024 an IARC working group classified talc as probably carcinogenic to humans in Monographs Volume 136, a statement about the strength of evidence rather than the size of risk in ordinary use.

What is the $5.5 billion Johnson & Johnson talc settlement?

In late July 2026 Johnson & Johnson disclosed a proposal to resolve approximately 76,000 pending ovarian cancer claims for at least around $5.5 billion, negotiated with a court-appointed mediator in the tort system rather than through bankruptcy. Reported terms include roughly $3 billion payable in 2027 with further payments in 2028, resolution within about 18 months, and a condition that plaintiffs’ firms representing at least 95 percent of eligible claims sign on. Mesothelioma claims and claims by people diagnosed after the settlement closes are excluded, and per-claim amounts have not been published.

Can I still file a talcum powder lawsuit in 2026?

The litigation remains active, but whether a specific claim can still be filed depends on your state’s statute of limitations, which commonly ranges from one to six years and may run from diagnosis, from the date you reasonably should have connected the illness to the product, or from a death. Timing now matters for a second reason: the proposed settlement covers pending claims, so someone diagnosed after it closes would need to bring an individual suit. Because those deadlines are strict and jurisdiction-specific, consult a licensed attorney promptly rather than relying on general guidance.

What happened to Johnson & Johnson’s bankruptcy strategy?

Johnson & Johnson made three attempts to resolve talc liability by assigning it to a subsidiary that then filed for Chapter 11. The first, filed in 2021, was dismissed by the Third Circuit in January 2023 on the grounds that the entity was not in financial distress. A second filing in 2023, accompanied by a proposal of roughly $8.9 billion, was also dismissed. A third prepackaged filing in 2024, with a present value of about $6.48 billion payable over 25 years, was rejected by a Texas bankruptcy court on March 31, 2025. The 2026 settlement proposal is the direct result of those failures.

How much do talcum powder lawyers charge?

Plaintiffs’ firms in mass torts almost always work on a contingency basis, typically taking somewhere between one-third and 40 percent of any recovery, with litigation costs such as expert fees and depositions handled separately. Initial consultations are usually free. Before signing a representation agreement, ask in writing how case costs are treated if the claim is unsuccessful, ask whether the firm will litigate the case itself or refer it to another firm, and ask whether it is currently disqualified in your jurisdiction.

What compensation have talcum powder claimants actually received?

Outcomes have varied enormously and headline verdicts are a poor guide to typical results. Several large jury awards were later reduced, vacated or reversed on appeal, and Johnson & Johnson has also won a meaningful number of defense verdicts. The largest gross award remains the Missouri judgment originally returned at approximately $4.69 billion and reduced to roughly $2.12 billion, which was paid with interest; the largest single-plaintiff award is the $1.56 billion Baltimore mesothelioma verdict of December 2025, which is being appealed. An aggregate settlement divided among tens of thousands of claimants produces far smaller individual figures, tiered by diagnosis and use. No one should assume a particular figure applies to their own case.